Manufacturer | Source: NPPA
Published On: 25-03-2026
Enforcement Date: 25 March, 2026
OM regarding Movement in Wholesale Price Index (WPI) for the preceding calendar year 2025 over the year 2024
The National Pharmaceutical Pricing Authority (NPPA) has notified a Wholesale Price Index (WPI) increase of 0.64956% for 2025 over 2024, allowing manufacturers to revise the Maximum Retail Price (MRP) of scheduled formulations under DPCO, 2013. Manufacturers may increase prices based on this WPI change without prior government approval, in accordance with Paragraph 16(2) of the Order.
The National Pharmaceutical Pricing Authority (NPPA) has announced the annual Wholesale Price Index (WPI) change of +0.64956% for the calendar year 2025 over 2024.
Key points include:
- Based on provisions under Paragraph 16(2) of the Drugs (Prices Control) Order (DPCO), 2013, manufacturers of scheduled formulations are permitted to increase the Maximum Retail Price (MRP) of their products in line with this WPI adjustment.
- The memorandum clarifies that such price revisions can be implemented without requiring prior approval from the Government, provided they adhere to DPCO provisions.
- This annual WPI-linked revision mechanism ensures that drug prices remain aligned with inflationary trends while maintaining regulatory oversight.
The notification has been issued for information and necessary action by all concerned stakeholders in the pharmaceutical sector.
Applicable For: Manufacturer
Reference Number: F. No. 8(144)/2026/D.P./NPPA-Div.-II
Notification Link